Jieyu He and Yongyue Wei contributed equally to the work.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Dear Editor,
Previous studies have found approximately a 30% cumulative incidence for thrombosis in critically unwell patients, almost all whom already present impaired platelets function and activity, with COVID-19 in the intensive care unit (ICU) [1, 2]. We aimed to explore the association between platelet-related laboratory indicators and prognosis in critically ill patients with COVID-19.
Anzeige
All the severe and critically ill COVID-19 patients (Table 1) diagnosed in Huangshi City, Hubei Province, China, till 6 March, 2020, were recruited in this study which were distributed in the three hospitals including Huangshi Central Hospital, Huangshi Hospital of Traditional Chinese Medicine, and Daye People’s Hospital. Laboratory examinations including routine blood tests, lymphocyte subsets, inflammatory or infection-related biomarkers, cardiac, renal, liver and coagulation function tests were obtained at admission and during hospitalization. The baseline laboratory measures with over 40% missing value were excluded from the analysis. Death in 28 days after admission to the hospital was the primary end point of this study. Patients discharge from hospital within 28 days or kept in hospitalization after 28 days were considered as censored outcome. Time-to-event outcome was defined for the following statistical models.
Table 1
Demographic and clinical characteristics at hospitalization of severe or critically ill COVID-19 patients
Characteristics
NMissing (%)
Total (n = 112)
Survived (n = 81)
Dead (n = 31)
Age [mean (SD)]
61.0 (14.9)
57.1 (13.8)
71.0 (13.0)
Male [n (%)]
73 (65.2)
54 (66.7)
19 (61.3)
Vital signs [mean (SD)]
Temperature (°C)
2 (1.8)
37.3 (0.8)
37.3 (0.8)
37.2 (0.8)
Heart rate (beats/min)
29 (25.9)
89.4 (17.7)
87.1 (16.7)
94.4 (19.0)
Respiratory rate (Breaths/min)
5 (4.5)
24.8 (5.6)
25.1 (5.9)
24.1 (4.9)
Blood pressure (mm Hg)
Diastolic
5 (4.5)
73.2 (13.7)
73.3 (14.7)
72.8 (11.0)
Systolic
5 (4.5)
124.9 (17.3)
124.0 (18.0)
127.0 (15.7)
Symptoms [n (%)]
Fever
91 (81.2)
67 (82.7)
24 (77.4)
Cough
86 (76.8)
62 (76.5)
24 (77.4)
Chest tightness
73 (65.2)
56 (69.1)
17 (54.8)
Fatigue
65 (58.0)
54 (66.7)
11 (35.5)
Shortness of breath
34 (30.4)
21 (25.9)
13 (41.9)
Phlegm
28 (25.0)
20 (24.7)
8 (25.8)
Dyspnea
25 (22.3)
14 (17.3)
11 (35.5)
Diarrhea
19 (17.0)
15 (18.5)
4 (12.9)
Headache
9 (8.0)
7 (8.6)
2 (6.5)
Myalgia
6 (5.4)
5 (6.2)
1 (3.2)
Sore throat
5 (4.5)
4 (4.9)
1 (3.2)
Nausea and vomiting
5 (4.5)
2 (2.5)
3 (9.7)
Imaging abnormalitya
18 (16.1)
13 (16.0)
5 (16.1)
No. of symptoms [n (%)]
0
2 (1.8)
2 (6.5)
1
4 (3.6)
4 (4.9)
2
15 (13.4)
10 (12.3)
5 (16.1)
3
20 (17.9)
15 (18.5)
5 (16.1)
4
30 (26.8)
23 (28.4)
7 (22.6)
5
23 (20.5)
16 (19.8)
7 (22.6)
6
12 (10.7)
8 (9.9)
4 (12.9)
≥ 7
6 (5.4)
5 (6.2)
1 (3.2)
Comorbidities [n (%)]
Hypertension
40 (35.7)
26(32.1)
14 (45.2)
Respiratory failure
27 (24.1)
16 (19.8)
11 (35.5)
Cardiovascular disease
17 (15.2)
10 (12.3)
7 (22.6)
Diabetes
21 (18.8)
15 (18.5)
6 (19.4)
Acute lung injury
14 (12.5)
9 (11.1)
5 (16.1)
COPDb
5 (4.5)
2 (2.5)
3 (9.7)
Bacterial pneumonia
3 (2.7)
2 (2.5)
1 (3.2)
Hepatic injury
3 (2.7)
3 (3.7)
Septic shock
3 (2.7)
2 (2.5)
1 (3.2)
Cerebral infarction
2 (1.8)
1 (1.2)
1 (3.2)
Acute kidney injury
1 (0.9)
1 (1.2)
Cerebral hemorrhage
1 (0.9)
1 (1.2)
Sepsis
1 (0.9)
1 (1.2)
N of comorbidities [n (%)]
0
46 (41.1)
36 (44.4)
10 (32.3)
1
26 (23.2)
20 (24.7)
6 (19.4)
2
19 (17.0)
13 (16.0)
6 (19.4)
3
13 (11.6)
7 (8.6)
6 (19.4)
4
4 (3.6)
2 (2.5)
2 (6.5)
5
1 (0.9)
1 (1.2)
0 (0)
≥ 6
3 (2.7)
2 (2.5)
1 (3.2)
Worst severity in hospital
Severe
63
63
0
Critical illness [n (%)]
49
18
31
SD standard deviation
aIncluding chest radiography and computed tomography (CT)
bChronic obstructive pulmonary disease
The platelet-related indicators included platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), thrombocytocrit (PCT), and platelet large cell ratio (P-LCR). Baseline indicators were dichotomized by the median to low and high groups. For each platelet-related indicator with repeated examinations during hospitalization, trajectory analysis was performed to cluster the patients based on the dynamic time-series trend of the corresponding indicator, using R package traj [3]. According to the requirement of the method, patients during hospitalization with less than four observations of the specific indicator were classified as a separate cluster. Cox proportional hazards model with adjustment for age, gender, number of comorbidities were applied to test the association between dynamic trajectory of platelet-related indicators and overall survival of COVID-19 patients.
The patients at admission with high PLT (HR 0.28; 95% CI 0.11–0.69; P = 0.0057; Fig. 1a) were associated with the preferred survival; however, patients with high PDW (HR 2.52; 95% CI 1.17–5.44; P = 0.0185; Fig. 1b), high MPV (HR 3.73; 95% CI 1.55–9.02; P = 0.0034; Fig. 1c), or high P-LCR (HR 3.00; 95% CI 1.40–6.41; P = 0.0046; Fig. 1d) were significantly associated with the worse survival. On the other hand, dynamic trajectory of PLT couldn’t distinguish patients’ survival (Fig. 1e). However, a similar dynamic trajectory pattern with rapid acceleration in the first 2 weeks followed by a considerable deceleration, was identified for MPV, PLCR, and PDW; patients with such pattern were significantly associated with about 2 to 5 times increased death hazard (Fig. 1f–h). All the above results remained significant after false discovery rate (FDR) control.
×
The findings of this study were accordant with several evidences suggesting platelets as well as related indicators participating in inflammation and prothrombotic responses in many viral infections [4]. The damage to endothelial cells leads to activation, aggregation, and retention of platelets, and the formation of thrombus at the injured site, which may cause a depletion of platelets and megakaryocytes, resulting in decreased platelets production and increased consumption. In addition to their traditional role in thrombosis and hemostasis, platelets mediate key aspects of inflammatory and immune processes [5]. Platelets have been reported to express surface receptors able to mediate binding and entry of various viruses [6]. In brief, paying close attention to the dynamics of platelet-related indicators of COVID-19 patients will undoubtedly improve our knowledge on diseases progression, but could also bring the improvement in therapeutic options for severe or critically ill patients.
Anzeige
Acknowledgements
We would like to thank all the medical staff for their efforts in collecting the data used in this study, and all the patients who consented to donate their data for analysis and the all medical staff members who are on the front line of caring for patients.
Ethics approval and consent to participate
The ethics committee of the hospitals (Huangshi Central Hospital, Huangshi Hospital of Traditional Chinese Medicine, and Daye People’s Hospital) waived the written informed consent from patients with COVID-19, and all the procedures being performed were part of the routine care.
Consent for publication
The informed consents of patients were waived by the Ethics Commission of the hospitals (Huangshi Central Hospital, Huangshi Hospital of Traditional Chinese Medicine, and Daye People’s Hospital) for the rapid emergence of this epidemic.
Competing interests
The authors declare no competing financial interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.